Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
HR 0.6 [0.43, 0.84]
2 studies · 1656 participants
Low

Number of participants experiencing disability progression · primary progressive multiple sclerosis

Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
HR 0.75 [0.58, 0.98]
1 study · 731 participants
Low